Carla Ramon-Duaso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carla Ramon-Duaso has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Arnau Busquets-Garcia
Cell-Type Mechanisms in Normal and Pathological Behavior Research Group, Neuroscience Research Program, Hospital del Mar Research Institute, Barcelona, Spain
5 shared publications - Antoni Camins
Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
3 shared publications - Júlia Pinho
Cell-Type Mechanisms in Normal and Pathological Behavior Research Group, Neuroscience Research Program, Hospital del Mar Research Institute
3 shared publications - Patricia Robledo
Integrative Pharmacology and Systems Neuroscience, Neuroscience Research Program, IMIM-Hospital del Mar Research Institute, 08003 Barcelona, Spain
3 shared publications Arnau Busquets-Garcia
Cell-Type Mechanisms in Normal and Pathological Behavior Research Group, Neuroscience Program, Hospital del Mar Research Institute, Barcelona, Spain
2 shared publicationsDavid Pubill
Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Institut de Biomedicina IBUB, Universitat de Barcelona, Barcelona, Spain
2 shared publications
Latest Publications
- 23 October 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24
Sex-Dependent Effects of Chronic Cannabinoid Treatment on Repetitive Behaviors and Amyloid Burden in APP/PS1 Mice
Introduction/Objective: The endocannabinoid system has been linked to the pathophysiology of Alzheimer’s Disease (AD), which is accompanied by both neuropathological and behavioral alterations. However, the contribution of this system to these specific processes remains incompletely understood. Here, we investigated the effects of ACEA, a selective agonist of type-1 cannabinoid receptors (CB1R), on repetitive behaviors and amyloid load in the APP/PS1 mouse model of AD. Methods: ACEA for 21 days at 3 months of age, a presymptomatic stage, was administered in male and female APP/PS1 mice and evaluated using non-cognitive behavioral tasks, amyloid load, and CB1R expression. results: We revealed sex-dependent differences in repetitive behaviors. Molecular analyses further demonstrated that ACEA also modulates amyloid burden and CB1R expression in a brain region- and sex-specific manner. Additionally, we characterized distinct amyloid plaque types, offering new insights into the relationship between cannabinoid signaling and AD neuropathology. Results: By using two complementary behavioral paradigms, the splash test and the marble-burying test, we assessed the impact of cannabinoid treatment on male and female mice, revealing sex-dependent differences in repetitive behaviors. Molecular analyses further demonstrated that ACEA also modulates amyloid burden and CB1R expression, considering brain-region- and sex-specific parameters. Additionally, the study characterized distinct amyloid plaque types, offering new insights into the relationship between cannabinoid signaling and AD neuropathology. Discussion: The present findings demonstrate that cannabinoid-based interventions can influence both behavioral outcomes and molecular alterations associated with AD. Importantly, the observed effects appear to depend on biological sex and specific brain regions, emphasizing the need to consider these variables when designing cannabinoid-based therapeutic strategies for AD. Conclusion: Collectively, the study’s findings highlight a modulatory role of cannabinoid drugs in both behavioral and molecular aspects of AD, supporting their potential relevance as therapeutic targets tailored to sex and brain region.
- 23 October 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24
Sex-Dependent Effects of Chronic Cannabinoid Treatment on Repetitive Behaviors and Amyloid Burden in APP/PS1 Mice
Introduction/Objective: The endocannabinoid system has been linked to the pathophysiology of Alzheimer’s Disease (AD), which is accompanied by both neuropathological and behavioral alterations. However, the contribution of this system to these specific processes remains incompletely understood. Here, we investigated the effects of ACEA, a selective agonist of type-1 cannabinoid receptors (CB1R), on repetitive behaviors and amyloid load in the APP/PS1 mouse model of AD. Methods: ACEA for 21 days at 3 months of age, a presymptomatic stage, was administered in male and female APP/PS1 mice and evaluated using non-cognitive behavioral tasks, amyloid load, and CB1R expression. results: We revealed sex-dependent differences in repetitive behaviors. Molecular analyses further demonstrated that ACEA also modulates amyloid burden and CB1R expression in a brain region- and sex-specific manner. Additionally, we characterized distinct amyloid plaque types, offering new insights into the relationship between cannabinoid signaling and AD neuropathology. Results: By using two complementary behavioral paradigms, the splash test and the marble-burying test, we assessed the impact of cannabinoid treatment on male and female mice, revealing sex-dependent differences in repetitive behaviors. Molecular analyses further demonstrated that ACEA also modulates amyloid burden and CB1R expression, considering brain-region- and sex-specific parameters. Additionally, the study characterized distinct amyloid plaque types, offering new insights into the relationship between cannabinoid signaling and AD neuropathology. Discussion: The present findings demonstrate that cannabinoid-based interventions can influence both behavioral outcomes and molecular alterations associated with AD. Importantly, the observed effects appear to depend on biological sex and specific brain regions, emphasizing the need to consider these variables when designing cannabinoid-based therapeutic strategies for AD. Conclusion: Collectively, the study’s findings highlight a modulatory role of cannabinoid drugs in both behavioral and molecular aspects of AD, supporting their potential relevance as therapeutic targets tailored to sex and brain region.
- Top Cited PapersOpen Access
- 11 February 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (2) , 467-488
Mitochondrial Ca2+ efflux controls neuronal metabolism and long-term memory across species
From insects to mammals, essential brain functions, such as forming long-term memories (LTMs), increase metabolic activity in stimulated neurons to meet the energetic demand associated with brain activation. However, while impairing neuronal metabolism limits brain performance, whether expanding the metabolic capacity of neurons boosts brain function remains poorly understood. Here, we show that LTM formation of flies and mice can be enhanced by increasing mitochondrial metabolism in central memory circuits. By knocking down the mitochondrial Ca 2+ exporter Letm1, we favour Ca 2+ retention in the mitochondrial matrix of neurons due to reduction of mitochondrial H + /Ca 2+ exchange. The resulting increase in mitochondrial Ca 2+ over-activates mitochondrial metabolism in neurons of central memory circuits, leading to improved LTM storage in training paradigms in which wild-type counterparts of both species fail to remember. Our findings unveil an evolutionarily conserved mechanism that controls mitochondrial metabolism in neurons and indicate its involvement in shaping higher brain functions, such as LTM.
- 11 February 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (2) , 467-488
Top Cited PapersOpen AccessMitochondrial Ca2+ efflux controls neuronal metabolism and long-term memory across species
From insects to mammals, essential brain functions, such as forming long-term memories (LTMs), increase metabolic activity in stimulated neurons to meet the energetic demand associated with brain activation. However, while impairing neuronal metabolism limits brain performance, whether expanding the metabolic capacity of neurons boosts brain function remains poorly understood. Here, we show that LTM formation of flies and mice can be enhanced by increasing mitochondrial metabolism in central memory circuits. By knocking down the mitochondrial Ca 2+ exporter Letm1, we favour Ca 2+ retention in the mitochondrial matrix of neurons due to reduction of mitochondrial H + /Ca 2+ exchange. The resulting increase in mitochondrial Ca 2+ over-activates mitochondrial metabolism in neurons of central memory circuits, leading to improved LTM storage in training paradigms in which wild-type counterparts of both species fail to remember. Our findings unveil an evolutionarily conserved mechanism that controls mitochondrial metabolism in neurons and indicate its involvement in shaping higher brain functions, such as LTM.
- Open Access
- 3 December 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Dorsal hippocampus mediates light–tone associations in male mice
Daily choices are often influenced by environmental cues that are not directly associated with reinforcers. This phenomenon, known as higher-order conditioning, can be studied using sensory preconditioning tasks in rodents. This behavioral paradigm involves the repeated pairing of two innocuous stimuli, such as a light and a tone, followed by a devaluation phase in which one stimulus is associated with an unconditioned stimulus, such as a mild footshock. The result is a conditioned response (e.g., freezing) to both the conditioned stimulus (direct learning) and the non-conditioned stimulus (mediated learning). In our study, we successfully established a light–tone sensory preconditioning task specifically in male mice, as sex differences were observed in both control experimental groups and in sensory preconditioning responses. We employed in vivo, freely moving fiber photometry to monitor neural activity in the dorsal and ventral subregions of the hippocampus in male mice during the formation of associations between innocuous stimuli and reinforcers. Additionally, we combined our sensory preconditioning task with chemogenetic approaches to investigate the roles of these hippocampal subregions in sensory preconditioning. Our results indicate that dorsal, but not ventral, CaMKII-positive neurons are involved in encoding innocuous stimuli during the preconditioning phase. Overall, we developed a novel light–tone sensory preconditioning protocol in male mice, enabling the detection of sex differences and furthering our understanding of how specific hippocampal subregions and cell types regulate complex cognitive processes.
- 3 December 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessDorsal hippocampus mediates light–tone associations in male mice
Daily choices are often influenced by environmental cues that are not directly associated with reinforcers. This phenomenon, known as higher-order conditioning, can be studied using sensory preconditioning tasks in rodents. This behavioral paradigm involves the repeated pairing of two innocuous stimuli, such as a light and a tone, followed by a devaluation phase in which one stimulus is associated with an unconditioned stimulus, such as a mild footshock. The result is a conditioned response (e.g., freezing) to both the conditioned stimulus (direct learning) and the non-conditioned stimulus (mediated learning). In our study, we successfully established a light–tone sensory preconditioning task specifically in male mice, as sex differences were observed in both control experimental groups and in sensory preconditioning responses. We employed in vivo, freely moving fiber photometry to monitor neural activity in the dorsal and ventral subregions of the hippocampus in male mice during the formation of associations between innocuous stimuli and reinforcers. Additionally, we combined our sensory preconditioning task with chemogenetic approaches to investigate the roles of these hippocampal subregions in sensory preconditioning. Our results indicate that dorsal, but not ventral, CaMKII-positive neurons are involved in encoding innocuous stimuli during the preconditioning phase. Overall, we developed a novel light–tone sensory preconditioning protocol in male mice, enabling the detection of sex differences and furthering our understanding of how specific hippocampal subregions and cell types regulate complex cognitive processes.
- 11 August 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (9) , 1844-1857
Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice
Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (Gs) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-Gs) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-Gs abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-Gs enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment.
- 11 August 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (9) , 1844-1857
Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice
Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (Gs) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-Gs) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-Gs abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-Gs enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment.
- Open Access
- 29 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
G protein-specific mechanisms in the serotonin 5-HT2A receptor regulate psychosis-related effects and memory deficits
G protein-coupled receptors (GPCRs) are sophisticated signaling machines able to simultaneously elicit multiple intracellular signaling pathways upon activation. Complete (in)activation of all pathways can be counterproductive for specific therapeutic applications. This is the case for the serotonin 2 A receptor (5-HT2AR), a prominent target for the treatment of schizophrenia. In this study, we elucidate the complex 5-HT2AR coupling signature in response to different signaling probes, and its physiological consequences by combining computational modeling, in vitro and in vivo experiments with human postmortem brain studies. We show how chemical modification of the endogenous agonist serotonin dramatically impacts the G protein coupling profile of the 5-HT2AR and the associated behavioral responses. Importantly, among these responses, we demonstrate that memory deficits are regulated by Gαq protein activation, whereas psychosis-related behavior is modulated through Gαi1 stimulation. These findings emphasize the complexity of GPCR pharmacology and physiology and open the path to designing improved therapeutics for the treatment of stchizophrenia.
- 29 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessG protein-specific mechanisms in the serotonin 5-HT2A receptor regulate psychosis-related effects and memory deficits
G protein-coupled receptors (GPCRs) are sophisticated signaling machines able to simultaneously elicit multiple intracellular signaling pathways upon activation. Complete (in)activation of all pathways can be counterproductive for specific therapeutic applications. This is the case for the serotonin 2 A receptor (5-HT2AR), a prominent target for the treatment of schizophrenia. In this study, we elucidate the complex 5-HT2AR coupling signature in response to different signaling probes, and its physiological consequences by combining computational modeling, in vitro and in vivo experiments with human postmortem brain studies. We show how chemical modification of the endogenous agonist serotonin dramatically impacts the G protein coupling profile of the 5-HT2AR and the associated behavioral responses. Importantly, among these responses, we demonstrate that memory deficits are regulated by Gαq protein activation, whereas psychosis-related behavior is modulated through Gαi1 stimulation. These findings emphasize the complexity of GPCR pharmacology and physiology and open the path to designing improved therapeutics for the treatment of stchizophrenia.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S633
PRECLINICAL EFFICACY OF A NEWLY IDENTIFIED COMPOUND IN DEPRESSIVE-LIKE PHENOTYPES IN MICE
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S633
Open AccessPRECLINICAL EFFICACY OF A NEWLY IDENTIFIED COMPOUND IN DEPRESSIVE-LIKE PHENOTYPES IN MICE
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S445
SENESCENCE IN ALZHEIMER'S DISEASE: A NEW TRANSGENIC MOUSE MODEL
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S445
Open AccessSENESCENCE IN ALZHEIMER'S DISEASE: A NEW TRANSGENIC MOUSE MODEL
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S881
HIPPOCAMPAL INVOLVEMENT IN MOUSE LIGHT-TONE SENSORY PRECONDITIONING
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S881
Open AccessHIPPOCAMPAL INVOLVEMENT IN MOUSE LIGHT-TONE SENSORY PRECONDITIONING
- 1 June 2020
- Published by Elsevier in Neuropharmacology
- Vol. 170, 108030
Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: Relevance for myotonic dystrophy 1
- 1 June 2020
- Published by Elsevier in Neuropharmacology
- Vol. 170, 108030
Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: Relevance for myotonic dystrophy 1
- 20 June 2019
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 33 (9) , 1170-1182
Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice
3,4-Methylenedioxymethamphetamine (MDMA) is still one of the most consumed drugs by adolescents. Its abuse is related with cognitive impairment, which seems due to maladaptive plasticity and neural stress. In turn, new hypotheses suggest that Alzheimer’s disease (AD) may be promoted by neural stressors. To test if there is an increase in vulnerability to AD after chronic MDMA consumption, we investigated the effects of this drug on recognition memory and its neurotoxic and neuroplastic effects in a transgenic mouse model of presymptomatic familiar AD (APP/PS1 dE9, Tg). MDMA-treated animals showed recognition memory deficits, regardless of genotype, which were accompanied by changes in plasticity markers. Tg mice showed an impaired expression of Arc compared with wild-type animals, but exposure to MDMA induced an increase in the expression of this factor of the same percentage in both genotypes. However, the expression of c-fos, BDNF and p-CREB was not significantly altered by MDMA treatment in Tg mice. Although Tg mice had higher free choline levels than wild-type mice (about 123%), MDMA did not modify these levels in any case, ruling out any specific effect of this drug on the acetylcholine pathway. MDMA treatment significantly increased the presence of cortical amyloid plaques, as well as Aβ40, Aβ42 and secreted APPβ levels in Tg mice. These plaques were accompanied by increased tau phosphorylation (S199), which does not seem to occur via the canonic pathway involving AKT, CDK5 or GSK3β. The present results support previous evidences that MDMA can contribute to the amyloid cascade.
- 20 June 2019
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 33 (9) , 1170-1182
Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice
3,4-Methylenedioxymethamphetamine (MDMA) is still one of the most consumed drugs by adolescents. Its abuse is related with cognitive impairment, which seems due to maladaptive plasticity and neural stress. In turn, new hypotheses suggest that Alzheimer’s disease (AD) may be promoted by neural stressors. To test if there is an increase in vulnerability to AD after chronic MDMA consumption, we investigated the effects of this drug on recognition memory and its neurotoxic and neuroplastic effects in a transgenic mouse model of presymptomatic familiar AD (APP/PS1 dE9, Tg). MDMA-treated animals showed recognition memory deficits, regardless of genotype, which were accompanied by changes in plasticity markers. Tg mice showed an impaired expression of Arc compared with wild-type animals, but exposure to MDMA induced an increase in the expression of this factor of the same percentage in both genotypes. However, the expression of c-fos, BDNF and p-CREB was not significantly altered by MDMA treatment in Tg mice. Although Tg mice had higher free choline levels than wild-type mice (about 123%), MDMA did not modify these levels in any case, ruling out any specific effect of this drug on the acetylcholine pathway. MDMA treatment significantly increased the presence of cortical amyloid plaques, as well as Aβ40, Aβ42 and secreted APPβ levels in Tg mice. These plaques were accompanied by increased tau phosphorylation (S199), which does not seem to occur via the canonic pathway involving AKT, CDK5 or GSK3β. The present results support previous evidences that MDMA can contribute to the amyloid cascade.